

Hepatitis A Vaccine (Inactivated Viral)

VAQTA®

Supplier: Merck Canada Inc.

(Adult presentation: 50 U/1.0 mL; Pediatric presentation: 25 U/0.5 mL)

INDICATIONS:

- See [Hepatitis A Vaccine Indications](#)

DOSES AND SCHEDULE: ^{A, B}

Routine series for Indigenous infants: ^{C, D} 2 doses given as 0.5 mL of VAQTA® (pediatric presentation-25 U) **IM** at 6 and 18 months of age.

Other eligible individuals:

6 months-17 years of age (inclusive): ^D 2 doses given as 0.5 mL of VAQTA® (pediatric presentation-25 U) **IM**, separated by 6 months.

18 years of age and older: ^D 2 doses given as 1.0 mL of VAQTA® (adult presentation-50 U) **IM**, separated by 6 months.

ADMINISTRATION:

No additional requirements.

BOOSTER DOSES:

No booster doses are recommended at this time.

SEROLOGICAL TESTING:

Serological testing may be indicated prior to immunization for select populations, see [Part 2 – Immunization of Special Populations](#). Post-vaccination serological testing is not indicated following a hepatitis A vaccine series.

CONTRAINDICATIONS:

1. History of an anaphylactic reaction to a previous dose of any hepatitis A vaccine, or to any component of VAQTA® or to latex.

PRODUCT COMPONENTS:

Potential allergens: neomycin, bovine albumin, latex.

Other components: formaldehyde, amorphous aluminum hydroxyphosphate sulfate, sodium borate.

^A Hepatitis A vaccines may be used interchangeably using the age-appropriate dose for the product being given.

^B Pediatric VAQTA® is approved for use in children 1-17 years of age (inclusive). However, NACI indicates that hepatitis A vaccine may be provided, beginning at 6 months of age, to infants who are at increased risk of infection or severe hepatitis A.

^C Indigenous children remain eligible for hepatitis A vaccine up to and including 18 years of age using the age-appropriate dosing and schedule.

^D For HIV positive individuals, provide 3 doses of vaccine at 0, 1 and 6 months.

Hepatitis A Vaccine (Inactivated Viral) VAQTA®

Supplier: Merck Canada Inc.

PRECAUTIONS:

Not applicable.

SPECIAL CONSIDERATIONS:

For more information related to pre-exposure prophylaxis against hepatitis A related to travel, refer clients to their local travel clinic.

ADVERSE EVENTS:

Local: soreness, redness.

Systemic: headache, fatigue, fever, malaise, nausea, vomiting, diarrhea.